ImpediMed Stock

ImpediMed Gross Margin

The Gross Margin of ImpediMed (IPD.AX) as of Aug 3, 2026 is 86.25 %. In the previous year, Gross Margin was 87.27 % — a change of -1.16% (lower).

Gross Margin

86.25 %

YoY

-1.16%

Last updated:

Gross Margin of ImpediMed is 2026 86.25 % . Gross Margin of ImpediMed was 2025 87.27 % . It decreases by -1.16% lower compared to the previous year.

For ImpediMed, the gross margin of 86.3% is up versus 80.9% a few years ago.

Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Gross Margin of ImpediMed is 86.25 % in 2026.

Gross Margin of ImpediMed changed from 87.27 % to 86.25 %, representing a -1.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — ImpediMed

All Key Metrics — ImpediMed